Aclaris Therapeutics (ACRS) Cash from Operations (2014 - 2026)

Aclaris Therapeutics' Cash from Operations history runs 13 years deep, the most recent figure standing at 18149000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations fell 39.0% year-over-year to 18149000.0 in Q1 2026; TTM through Mar 2026 was 52205000.0, a 323.85% decrease from a year earlier, with the FY2025 full-year figure at 47113000.0, down 134.68% from the prior year.
• Cash from Operations retreated to 18149000.0 in Q1 2026 per ACRS's latest filing, from 13131000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 22000000.0 in Q3 2024 and bottomed at 26353000.0 in Q1 2023.
• The 5-year median for Cash from Operations is 13131000.0 (2025), against an average of 13601705.88.
• Across the five-year window, Cash from Operations plunged 214.15% in 2023 and soared 189.59% in 2024, its largest moves.
• Year by year, Cash from Operations stood at 19115000.0 in 2022, then surged by 64.63% to 6761000.0 in 2023, then slumped by 32.2% to 8938000.0 in 2024, then slumped by 46.91% to 13131000.0 in 2025, then tumbled by 38.21% to 18149000.0 in 2026.
• Per Business Quant, the three latest ACRS Cash from Operations figures stand at 18149000.0 (Q1 2026), 13131000.0 (Q4 2025), and 10932000.0 (Q3 2025).